(6th May, 2014);As per new findings by investigators from King’s College London, Eczema caused by defects in the skin could reduce the risk of developing skin cancer. The immune response generated by eczema could help prevent tumour formation by shedding potentially cancerous cells from the skin.
According to the WHO, skin cancer is a common and growing problem, accounting for 1 in every 3 cancers diagnosed worldwide. Also recent findings suggest that malignant melanoma, the most dangerous form of skin cancer, is now five times more common in the UK than it was in the 1970s. Eczema can result from the loss of structural proteins in the outermost layers of the skin, leading to a defective skin barrier. Genetically engineered mice lacking three skin barrier proteins (‘knock-out’ mice) were used in the King’s study to replicate some of the skin defects found in eczema sufferers.
There is ongoing debate surrounding allergic diseases and their impact on the likelihood of developing cancer, with some studies suggesting that eczema is associated with a reduced risk of skin cancer. However, it is difficult to draw firm conclusions based on studies of human populations because eczema symptoms vary in severity and drugs used to treat the condition might also influence cancer. Published in eLife, the study by researchers at King’s College London is the first to show that allergy caused by the skin defects could actually protect against skin cancer.
The researchers, funded by the Medical Research Council (MRC), the Wellcome Trust and Cancer Research UK, compared the effects of two cancer-causing chemicals in normal mice and mice with the barrier defect (the knock-out mice). The number of benign tumours per mouse was six times lower in knock-out mice than in normal mice. The findings suggest that defects in the epidermal barrier protected the genetically engineered mice against benign tumour formation.
Researchers found that both types of mice were equally susceptible to acquiring cancer-causing mutations. However, an exaggerated inflammatory reaction in knock-out mice led to enhanced shedding of potentially cancerous cells from the skin. This cancer-protective mechanism bears similarities to that which protects skin from environmental assaults such as bacteria.
"We are excited by our findings as they establish a clear link between cancer susceptibility and an allergic skin condition in our experimental model. They also support the view that modifying the body’s immune system is an important strategy in treating cancer", said by Professor Fiona Watt, Director of the Centre for Stem Cells and Regenerative Medicine. "I hope our study provides some small consolation to eczema sufferers – that this uncomfortable skin condition may actually be beneficial in some circumstances."
Dr Mike Turner, Head of Infection and Immunobiology at the Wellcome Trust said, "Skin cancer is on the rise in many countries and any insight into the body’s ability to prevent tumour formation is valuable in the fight against this form of cancer. These findings that eczema can protect individuals from skin cancer support theories linking allergies to cancer prevention and open up new avenues for exploration whilst providing some (small) comfort for those suffering from eczema."
